Acquired Cystic Disease-Associated Renal Cell Carcinoma: A Systematic Review and Meta-analysis

Nguyen Xuong Duong; Minh-Khang Le; Tuan Thanh Nguyen; Duy Duc Nguyen; Huy Gia Vuong; Tetsuo Kondo; Takahiko Mitsui

doi:10.1016/j.clgc.2024.02.001

Acquired Cystic Disease-Associated Renal Cell Carcinoma: A Systematic Review and Meta-analysis

Clin Genitourin Cancer. 2024 Feb 14;22(3):102050. doi: 10.1016/j.clgc.2024.02.001. Online ahead of print.

Authors

Nguyen Xuong Duong¹, Minh-Khang Le², Tuan Thanh Nguyen³, Duy Duc Nguyen⁴, Huy Gia Vuong⁵, Tetsuo Kondo², Takahiko Mitsui⁶

Affiliations

¹ Department of Urology, University of Yamanashi Graduate School of Medical Sciences, Chuo-city, Japan; Department of Urology, Cho Ray Hospital, Ho Chi Minh City, Vietnam. Electronic address: dr.duongnguyenxuong@gmail.com.
² Department of Pathology, University of Yamanashi Graduate School of Medical Sciences, Chuo-city, Japan.
³ Department of Urology, Cho Ray Hospital, Ho Chi Minh City, Vietnam; Department of Urology, University of Medicine and Pharmacy at Ho Chi Minh city, Vietnam.
⁴ Department of Pathology, University Medical Center of HCMC, Ho Chi Minh City, Vietnam.
⁵ Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA.
⁶ Department of Urology, University of Yamanashi Graduate School of Medical Sciences, Chuo-city, Japan.

PMID: 38502982
DOI: 10.1016/j.clgc.2024.02.001

Abstract

Acquired cystic disease-associated renal cell carcinoma (ACD-RCC) is a common subtype of renal cell carcinoma (RCC) in end-stage renal disease (ESRD) patients. The current systematic review and meta-analysis was performed to evaluate the clinicopathological, and genetic characteristics of patients with ACD-RCC. A systematic search on three electronic databases including the Pubmed, Scopus, and Web of Science databases were performed until December 31, 2022. A meta-analysis was performed following the PRISMA 2020 Guidelines. Of 888 identified articles, full-text screening in 69 articles, there were 26 articles analyzed, with a total of 2314 tumors in 2199 patients, including 418 ACD-RCC tumors in 363 patients, 1340 clear cell RCC (ccRCC) tumors, 308 papillary RCC (pRCC) tumors. Most ACD-RCC patients were male (80.2%). All the ACD-RCC patients underwent prior dialysis with 148.2 months of mean dialysis duration. There were 8.7%, 3.4%, and 5.8% tumors at the T3-4 stage, N1 stage, and M1 stage, respectively. The mean overall survival of ACD-RCC patients was 39.6 months (95% CI, 26.6-52.5). Compared to ccRCC and pRCC, ACD-RCC patients had a longer duration of dialysis (MD: 103.5 and 31.77 months, respectively; 95% CI: [75.48; 131.53] and [0.95; 62.58], respectively), and a higher rate of multifocal tumors (MD: 3.46 and 2.45 tumors, respectively; 95% CI [1.71; 6.98] and [1.26; 4.79], respectively). Regarding genetic characteristics, chromosomes 3 and 16 were the 2 most frequent chromosomal aberrations. The missense mutation in KMT2C (25%) and TSC2 (18.75%) were the 2 most common gene mutations in ACD-RCC. In conclusion, the ACD-RCC subtype exhibited several distinct clinicopathological and genetic characteristics compared to others RCC subtypes. Further researchs are needed to assess the survival outcome and the genetic characteristics of this subtype.

Keywords: Acquired cystic kidney disease; End-stage renal disease; Kidney Cancer; Renal Cancer; Renal cell adenocarcinoma.

Publication types

Review